NCT06704100View on ClinicalTrials.gov

Oral Fosamprenavir + Sodium Alginate for GERD

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

February 28, 2028

Study Completion Date

June 1, 2028

Conditions
Refractory Gastroesophageal Reflux DiseaseGastroesophageal Reflux Disease
Interventions
DRUG

Fosamprenavir Calcium & Sodium Alginate

1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID

OTHER

Placebo

15 ml oral solution containing 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate

Trial Locations (1)

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER